MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will ...

Shares of MNKD stock opened at $5.34 on Wednesday. MannKind has a 1-year low of $3.97 and a 1-year high of $7.63. The company has a market capitalization of $1.47 billion, a price-to-earnings ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Highlights,MannKind Corporation received multiple rating upgrades, reflecting changing market evaluations.,The company reported earnings aligning with projections, with revenue surpassing prior ...

This prediction has just been started. It does not have a price yet.. This prediction currently runs until 27.02.26. The prediction end date can be changed by Wedbush at any time.

Learn more here. Operator Good afternoon, and welcome to the MannKind Corporation fourth quarter and year-end 2024 financial results earnings call. As a reminder, this call is being recorded on ...

MannKind Corp (NASDAQ:MNKD) reported a 31% increase in fourth-quarter revenues, reaching $77 million, and a 43% increase for the full year, totaling $286 million. The company successfully reduced ...

Good afternoon and welcome to the MannKind Corporation Fourth Quarter and Year End 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on February 26, 2025 and will be ...

and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a ...